A Study Evaluating APG777 in Atopic Dermatitis
Public ClinicalTrials.gov record NCT06395948. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Two-part, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of APG777 in Patients With Moderate-to-severe Atopic Dermatitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a two-part study that will evaluate the safety and efficacy of APG777 in participants with moderate-to-severe Atopic Dermatitis (AD). Part A (Proof-of-concept) and Part B (Dose-regimen Finding) will evaluate the safety and efficacy of various induction and maintenance dose regimens of APG777 compared to placebo. The study duration for any individual participant will be up to 106 weeks which includes: screening, induction, maintenance, and post-treatment follow-up periods. Participants randomized in Part A are not permitted to participate in Part B.
Study identification
- NCT ID
- NCT06395948
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 470 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 29, 2024 (Actual)
- Primary completion
- Nov 2026 (Estimated)
- Completion
- Jun 2028 (Estimated)
- Last update posted
- Oct 13, 2026
2024 – 2028
United States locations
- U.S. sites
- 29
- U.S. states
- 20
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational Site | Fountain Valley | California | 92708 | — |
| Investigational Site | Los Angeles | California | 90024 | — |
| Investigational Site | San Diego | California | 92123 | — |
| Investigational Site | New Haven | Connecticut | 06519 | — |
| Investigational Site | Coral Gables | Florida | 33134 | — |
| Investigational Site | Jacksonville | Florida | 32256 | — |
| Investigational Site | Margate | Florida | 33063 | — |
| Investigational Site | Douglasville | Georgia | 30135 | — |
| Investigational Site | Chicago | Illinois | 60657 | — |
| Investigational Site | Skokie | Illinois | 60077 | — |
| Investigational Site | West Lafayette | Indiana | 47906 | — |
| Investigational Site | Bowling Green | Kentucky | 42104 | — |
| Investigational Site | Rockville | Maryland | 20850 | — |
| Investigational Site | Detroit | Michigan | 48202 | — |
| Investigational Site | Troy | Michigan | 48084 | — |
| Investigational Site | Portsmouth | New Hampshire | 13801 | — |
| Investigational Site | New York | New York | 10023 | — |
| Investigational Site | Wilmington | North Carolina | 28403 | — |
| Investigational Site | Boardman | Ohio | 44512 | — |
| Investigational Site | Mason | Ohio | 45040 | — |
| Investigational Site | Portland | Oregon | 97201 | — |
| Investigational Site | Pittsburgh | Pennsylvania | 15213 | — |
| Investigational Site | Charleston | South Carolina | 29425 | — |
| Investigational Site | Nashville | Tennessee | 37215 | — |
| Investigational Site | Dallas | Texas | 75230 | — |
| Investigational Site | Dallas | Texas | 75235 | — |
| Investigational Site | San Antonio | Texas | 78213 | — |
| Investigational Site | Norfolk | Virginia | 23502 | — |
| Investigational Site | Mill Creek | Washington | 98012 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 65 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06395948, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 13, 2026 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06395948 live on ClinicalTrials.gov.